Mechanism of action of new antiepileptic drugs;Mechanizmy działania nowych leków przeciwpadaczkowych

Postepy Psychiatrii i Neurologii

Volumn 17, Issue 1, 2008, Pages 53-60

  Sobolewska, Alicja ^a   Szyndler, Janusz ^b   Turzyńska, Danuta ^a   Płaźnik, Adam ^a,b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antiepileptic drugs; Epilepsy; Mechanism of action

Indexed keywords

2 AMINO 2 (3 CARBOXYCYCLOBUTYL) 3 (9 THIOXANTHYL)PROPIONIC ACID; 4 CARBOXY 2 METHYLPHENYLGLYCINE; ANTICONVULSIVE AGENT; BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CENTRAL DEPRESSANT AGENT; EGLUMETAD; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; NIFEDIPINE; NIMODIPINE; OXCARBAZEPINE; PHENYTOIN; SODIUM CHANNEL BLOCKING AGENT; TIAGABINE; TOPIRAMATE; WIGRAINE;

DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPILEPSY; GABAERGIC TRANSMISSION; REVIEW;

EID: 77953397121     PISSN: 12302813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Jedrzejczak J, Zwoliński P. Padaczka. W: Kozubski W, Liberski PP. red. Choroby układu nerwowego. Warszawa: PZWL; 2004. s. 442-466.
2. Jedrzejczak J. Padaczka. Lublin: Czelej; 2006.
3. Parton M, Cockerell ChO. Epilepsy - the aetiology and pathogenesis. Hosp Pharmacist. 2003; 10: 288-95.
4. Komisja Klasyfikacji i Terminologii. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989; 30 (4): 389-99.
5. McDonald JW, Garofalo EA, Hood T, Sackellares JC, Gilman S, McKeever PE, Troncoso JC, Johnston MV. Altered excitatory and inhibitory amino acids receptor binding in hippocampus of patients with temporal lobe epilepsy. Ann Neurol. 1991; 29 (5): 529-41.
6. Mathern GW, Pretorius JK, Kornblum HI, Mendoza D, Lozada A, Leite JP, Chimelli LM, Fried I, Sakamoto AC, Assirati JA, Lévesque MF, Adelson PD, Peacock WJ. Human hippocampal AMPA and NMDA and mRNA levels in temporal lobe epilepsy patients. Brain. 1997; 120 (Pt 11): 1937-59.
7. Sacaan A, Bymaster F, Schoepp D. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. J Neurochem. 1992; 59 (1): 245-51.
8. Chapman AG, Yip PK, Yap JS, Quinn LP, Tang E, Harris JR, Meldrum BS. Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarbolxylic acid). Eur J Pharmacol. 1999; 368 (1): 17-24.
9. Alexander GM, Godwin DW. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Res. 2006; 71 (1): 1-22.
10. Ghauri M, Chapman AG, Meldrum BS. Convulsant and anticonvulsant actions of agonists and antagonists of group III mGluRs. Neuroreport. 1996; 7 (9): 1469-74.
11. Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, Laurie D, Sommer B, Varney MA, Hess SD, Johnson EC, Kuhn R, Urwyler S, Sauer D, Portet C, Schmutz M, Nicoletti F, Flor PJ. (R,S)-4-phosphonophenylglycyne, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther. 1999; 289 (3): 1978-87.
12. Kłodzińska A, Chojnacka-Wójcik E, Pilc A. Selective group II glutamate metabotropic receptor agonist LY354740 attenuates pentetrazole- and picrotoxin-induced seizures. Pol J Pharmacol. 1999; 51 (6): 543-5.
13. Kostowski W. Kwas γ-aminomasłowy (GABA). W: Kostowski W, Pużyński S. red. Psychofarmakologia doświadczalna i kliniczna. Warszawa: PZWL; 1996. s 98-103.
14. Czapiński P, Blaszczyk B, Czuczwar SJ. Mechanism of action of antiepileptic drugs, Curr Top Med Chem. 2005; 5 (1): 3-14.
15. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002; 51 (1-2): 31-71.
16. Lasoń W. Receptorowe mechanizmy działania leków przeciwpadaczkowych. W: Jóźwiak S. red. Postepy w diagnostyce i leczeniu chorób układu nerwowego u dzieci. Lublin: BiFolium; 2004. s 11-21.
17. Errington AC, Stöhr T, Less G. Voltage gated ion channels: targets for anticonvulsant drugs. 2005; 5 (1): 15-30.
18. Shouse MN, Staba RJ, Ko PY, Saquib SF, Farber PR. Monoamines and seizures: microdialysis findings in locus ceruleus and amygdala before and during amygdala kindling. Brain Res. 2001; 892 (1): 176-92.
19. Cavalheiro EA, Leite JP, Bortolotto ZA, Turski WA, Ikonomidou C, Turski L. Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia. 1991; 32 (6): 778-82.
20. Wada Y, Nakamura M, Hasegawa H, Yamaguchi N. Role of serotonin receptor subtype in seizures kindled from the feline hippocampus. Neurosci Lett. 1992; 141 (1): 21-4.
21. Wada Y, Shiraishi J, Nakamura M, Koshino Y. Role of serotonin receptor subtypes in the development of amygdaloid kindling in rats. Brain Res. 1997; 747 (2): 338-42.
22. Ure JA, Perassolo M. Update on the pathophysiology of the epilepsies. J Neurol Sci. 2000; 177 (1): 1-17.
23. Clinckers R, Smolders J, Meurs A, Ebinger G, Michotte Y. Anticonvulsant action of GBR-12909 and citalopram against acute experimentally induced limbic seizeres. Neuropharmacology. 2004; 47 (7): 1053-61.
24. Weinshenker D, Szot P. The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol Ther. 2002; 94 (3): 213-33.
25. Devinsky O, Emoto S, Goldstein DS, Stull R, Porter RJ, Theodore WH, Nadi NS. Cerebrospinal fluid and serum levels of dopa, catechols, and monoamine metabolites in patients with epilepsy. Epilepsia. 1992; 33 (2): 263-70.
26. Corcoran ME, Mason ST. Role of forebrain catecholamines in amygdaloid kindling. Brain Res. 1980; 190 (2): 473-84.
27. Jimenez-Riviera C, Voltura A, Weiss GK. Effects of locus ceruleus stimulation on the development of kindled seizures. Exp Neurol. 1987; 95 (1): 13-20.
28. Favale E, Rubino V, Mainardi P, Lunardi G, Albano C. Anticonvulsant effect of fluoxetine in humans. Neurology. 1995; 45 (10): 1926-7.
29. Freitas RM, Sousa FC, Viana GS, Fonteles MM. Effects of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus. Neurosci Lett. 2006; 408 (2): 79-83.
30. Zienowicz M, Wisłowska A, Lehner M, Taracha E, Skórzewska A, Maciejak P, Płaźnik A. The effects of fluoxetine in a model of chemically induced seizure-behavioral and immunocytochemical study. Neurosci Lett. 2005; 373 (3): 226-31.
31. Woldbye DP, Larsen PJ, Mikkelsen JD, Klemp K, Madsen TM, Bolwing TG. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat Med. 1997; 3 (7): 761-4.
32. Barton ME, Shannon HE. The seizure-related phenotype of brain-derived neurotrophic factor knockdown mice. Neuroscience. 2005; 136 (2): 563-9.
33. Larmet Y, Reibel S, Carnahan J, Nawa H, Marescaux C, Depaulis A. Protective effects of brain-derived neurotrophic factor on the development of hippocampal kindling in the rat. Neuroreport. 1995; 6 (14): 1937-41.
34. McNamara JO, Byrne MC, Dasheiff RM, Fitz JG. The kindling model of epilepsy: a review. Prog Neurobiol. 1980; 15 (2): 139-59.
35. Dalby NO, Nielsen EB. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res. 1997; 28 (1): 63-72.
36. Alonso-deFlorida F, Delgado JM. Lasting behavioral and EEG changes in cats induced by prolonged stimulation of the amygdala. Am J Physiol. 1958; 193 (1): 223-9.
37. Goddard GV. Development of epileptic seizures through brain stimulation at low intensity. Nature. 1967; 214 (5092): 1020-1.
38. Ryglewicz D. Historia leczenia padaczki. Neurol i Psych. 2004; 4: 93-6.
39. Smith PEM, Wallace SJ. Padaczka - kliniczny przewodnik. Bielsko-Biala: α-medica press; 2003.
40. Czapiński P. Leczenie padaczki u osób dorosłych: wybór leku i prowadzenie terapii w padaczce nowozdiagnozowanej. Neurol i Psych. 2004; 1: 60-6.
41. Ahmad S, Fowler LJ, Whitton PS. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res. 2004; 1029 (1): 41-7.
42. Shuaib A, Mahmood RH, Wishart T, Kanthan R, Murabit MA, Ijaz S, Miyashita H, Howlett W. Neuroprotective effect of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Res. 1995; 702 (1-2): 199-206.
43. Bacher A, Zornow MH. Lamotrigine inhibits extracellular glutamate accumulation during transient global cerebral ischemia in rabbits. Anesthesiology. 1997; 86 (2): 459-63.
44. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs. 2001; 15 (2): 137-63.
45. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia. 1995; 36 (6): 612-26.
46. Stables JP, Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perrucca E. Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference. Epilepsy Res. 1995; 22 (3): 235-46.
47. Borowicz KK, Luszczki JJ, Duda AM, Czuczwar SJ. Effect of topiramate on the anticonvulsant activity of conventional antiepileptic drugs in two models of experimental epilepsy. Epilepsia. 2003; 44 (5): 640-6.
48. Reimann W. Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Eur J Pharmacol. 1983; 94 (3-4): 341-4.
49. Schlicker E, Reimann W, Göthert M. Gabapentin decreases monoamine release without affecting acetylocholine release in the brain. Arzneimittelforschung. 1985; 35 (9): 1347-9.
50. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure. 2003; 12 (5): 300-6.
51. Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci. 2004; 20 (6): 1566-76.
52. 2+ current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001; 306 (1-2): 5-8.
53. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002; 43 (1): 9-18.
54. Luszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Wojcik-Cwikla J, Ratnaraj N, Patsalos PN, Czuczwar SJ. Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. Eur Neuropsychopharmacol. 2005; 15 (6): 609-16.
55. Yan HD, Ji-gun C, Ishihara K, Nagayama T, Serikawa T, Sasa M. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia. 2005; 46 (8): 1170-7.
56. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eight Eilat Conference (EILAT VIII). Epilepsy Res. 2007; 73 (1): 1-52.
57. Pollard JR, French J. Antiepileptic drugs in developoment. Lancet Neurol. 2006; 5 (12): 1064-7.